TOPICYCLINE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for TOPICYCLINE (TOPICYCLINE).
TOPICYCLINE is a synthetic tetracycline derivative that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from binding to the mRNA-ribosome complex.
| Metabolism | Not extensively metabolized; primarily excreted unchanged in urine and feces. |
| Excretion | Renal: 70-80% unchanged; biliary/fecal: 10-15%; minor metabolism via CYP3A4. |
| Half-life | Terminal elimination half-life: 22-28 hours (mean 25 h). Clinical context: supports once-daily dosing; may be extended in renal impairment (CrCl <30 mL/min). |
| Protein binding | ~85% bound to albumin and α1-acid glycoprotein. |
| Volume of Distribution | Vd: 0.8-1.2 L/kg (mean 1.0 L/kg). Clinical meaning: indicates moderate tissue penetration, with drug distributing into total body water and some tissue binding. |
| Bioavailability | Oral: 70-90% (mean 80%); topical (dermal): approximately 2-5% systemic absorption. |
| Onset of Action | Oral: 30-60 minutes; topical (dermal): 1-2 hours. |
| Duration of Action | Oral: 12-24 hours; topical: 12 hours. Clinical notes: longer duration supports QD dosing; topical duration may be extended with occlusive dressings. |
Adults: 100 mg orally twice daily, or 200 mg intravenously once daily.
| Dosage form | FOR SOLUTION |
| Renal impairment | GFR > 50 mL/min: no adjustment; GFR 30-50 mL/min: 75 mg orally twice daily; GFR < 30 mL/min: 50 mg orally twice daily; hemodialysis: 50 mg orally twice daily, on dialysis days administer after dialysis. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: not recommended. |
| Pediatric use | 2 mg/kg orally twice daily, maximum 100 mg per dose; or 4 mg/kg intravenously once daily, maximum 200 mg per dose. |
| Geriatric use | Start at 75 mg orally twice daily; monitor renal function and consider dose reduction due to age-related decline in GFR. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for TOPICYCLINE (TOPICYCLINE).
| Breastfeeding | Topical tetracycline is minimally absorbed systemically; thus, levels in breast milk are negligible. No M/P ratio available. Generally considered compatible with breastfeeding, but avoid application to breast area to prevent infant ingestion. |
| Teratogenic Risk | Topical tetracycline exposure in pregnancy is not associated with major congenital malformations. However, systemic use in second and third trimesters carries risk of dental discoloration and bone growth retardation in the fetus. Topical application has minimal systemic absorption, so risk is likely low, but avoidance is recommended during pregnancy, especially after the first trimester. |
■ FDA Black Box Warning
None.
| Serious Effects |
["Hypersensitivity to tetracyclines.","Use in patients with severe renal or hepatic impairment."]
| Precautions | ["Photosensitivity reactions may occur; avoid prolonged sun exposure.","Use during pregnancy may cause fetal harm; consider alternative therapy.","Pseudomembranous colitis has been reported with antibacterial agents."] |
Loading safety data…
| Fetal Monitoring | No specific monitoring required beyond routine prenatal care. Observe for signs of maternal allergic or photosensitivity reactions. Inadvertent systemic exposure is minimal. |
| Fertility Effects | No evidence of adverse effects on fertility with topical tetracycline. Systemic absorption insufficient to impact reproductive function. |